Dual-subtype FIV vaccine (Fel-O-Vax® FIV) protection against a heterologous subtype B FIV isolate

Pu, Ruiyu; Coleman, James; Coisman, James G.; Sato, Eiji; Tanabe, Taishi; Arai, Maki; Yamamoto, Janet K.

doi:10.1016/j.jfms.2004.08.005

Cited by 48 publications

(42 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overlapping 15mer peptides with 11 aa overlap were synthesized based on subtype-A FIV p24 sequence and the 3-4 consecutive peptides were pooled to derive 17 FIV p24 peptide pools (Fp1-Fp17). Recombinant FIV p24 proteins were produced using E. coli expression system (Coleman et al, 2005). Feline IFNγELISpot development was performed according to manufacturer's protocol (R&D Systems).…”

Section: Computational Modeling For T-cell Immunity-based Fiv Vaccinesmentioning

confidence: 99%

Advances in FIV vaccine technology

Uhl

Martin

Coleman

et al. 2008

Veterinary Immunology and Immunopathology

View full text Add to dashboard Cite

Advances in vaccine technology are occurring in the molecular techniques used to develop vaccines and in the assessment of vaccine efficacy, allowing more complete characterization of vaccine-induced immunity correlating to protection. FIV vaccine development has closely mirrored and occasionally surpassed the development of HIV-1 vaccine, leading to first licensed technology. This review will discuss technological advances in vaccine designs, challenge infection assessment, and characterization of vaccine immunity in the context of the protection detected with prototype and commercial dual-subtype FIV vaccines and in relation to HIV-1.

show abstract

Section: Computational Modeling For T-cell Immunity-based Fiv Vaccinesmentioning

confidence: 99%

Advances in FIV vaccine technology

Uhl

Martin

Coleman

et al. 2008

Veterinary Immunology and Immunopathology

View full text Add to dashboard Cite

show abstract

“…This vaccine was reported to prevent the infection of subtypes A, B and D FIV but we have no information of its efficacy against subtype C [10,18,19,22,23]. Previous studies indicated the presence of subtype C FIV in Japan; however, it has been considered that subtype C virus is rare in Japan [13,15].…”

mentioning

confidence: 99%

An Updated Nation-Wide Epidemiological Survey of Feline Immunodeficiency Virus (FIV) Infection in Japan

Nakamura

URA

et al. 2010

J. Vet. Med. Sci.

View full text Add to dashboard Cite

ABSTRACT. An updated nation-wide epidemiological survey of feline immunodeficiency virus (FIV) infection was conducted in Japan. Blood samples were collected from 1,770 outdoor accessing cats from March to October 2008. Serologically, 410 cats (23.2%) were positive for anti-FIV antibody. Proviral DNA of the FIV env V3-V5 region isolated from 348 cases could be phylogenetically analyzed. The present study disclosed a geographic distribution of four subtypes (A, B, C and D) of FIV in Japan. Even though an FIV vaccine was introduced in Japan, we do not currently know whether this vaccine is effective against all strains of FIV in Japan or not. Therefore, close attention still has to be paid to epidemic and genotypic trends of FIV.KEY WORDS: epidemiological survey, feline immunodeficiency virus, subtypes.

show abstract

“…The infection it establishes in domestic cats resembles human AIDS, causing progressive immune deficiency; therefore, it is considered a model to test possible vaccination strategies against HIV-1. Vaccines consisting of inactivated virus and/or inactivated virus-infected cells have been shown to provide some protection against homologous and, sometimes, against heterologous challenges as well (7,14,16,19,27). However, the protective effects exerted have shown strong limitations or have proved difficult to reproduce (1,5,15).…”

mentioning

confidence: 99%

Evaluation of Feline Monocyte-Derived Dendritic Cells Loaded with Internally Inactivated Virus as a Vaccine against Feline Immunodeficiency Virus

Freer

Matteucci

Mazzetti

et al. 2008

Clin Vaccine Immunol

View full text Add to dashboard Cite

Dendritic cells are the only antigen-presenting cells that can present exogenous antigens to both helper and cytolytic T cells and prime Th1-type or Th2-type cellular immune responses. Given their unique immune functions, dendritic cells are considered attractive "live adjuvants" for vaccination and immunotherapy against cancer and infectious diseases. The present study was carried out to assess whether the reinjection of autologous monocyte-derived dendritic cells loaded with an aldithriol-2-inactivated primary isolate of feline immune deficiency virus (FIV) was able to elicit protective immune responses against the homologous virus in naive cats. Vaccine efficacy was assessed by monitoring immune responses and, finally, by challenge with the homologous virus of vaccinated, mock-vaccinated, and healthy cats. The outcome of challenge was followed by measuring cellular and antibody responses and viral and proviral loads and quantitating FIV by isolation and a count of CD4 ؉ /CD8 ؉ T cells in blood. Vaccinated animals exhibited clearly evident FIV-specific peripheral blood mononuclear cell proliferation and antibody titers in response to immunization; however, they became infected with the challenge virus at rates comparable to those of control animals.

show abstract

Dual-subtype FIV vaccine (Fel-O-Vax® FIV) protection against a heterologous subtype B FIV isolate

Cited by 48 publications

References 14 publications

Advances in FIV vaccine technology

Advances in FIV vaccine technology

An Updated Nation-Wide Epidemiological Survey of Feline Immunodeficiency Virus (FIV) Infection in Japan

Evaluation of Feline Monocyte-Derived Dendritic Cells Loaded with Internally Inactivated Virus as a Vaccine against Feline Immunodeficiency Virus

Contact Info

Product

Resources

About